Securities code: 603963 securities abbreviation: Dali Pharmaceutical Co.Ltd(603963) Announcement No.: 2021-036 Dali Pharmaceutical Co.Ltd(603963) about participation
Announcement on failure of centralized volume procurement of inter provincial alliance of Chinese patent medicine
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Dali Pharmaceutical Co.Ltd(603963) (hereinafter referred to as “the company”) recently participated in the quotation for centralized procurement of inter provincial alliance of Chinese patent medicines organized by the office of the leading group for centralized procurement of inter provincial alliance of Chinese patent medicines. According to the publicity of the proposed results of centralized procurement of inter provincial Alliance of Chinese patent medicines issued by the office of the leading group for centralized procurement of inter provincial alliance of Chinese patent medicines , the company’s product Shenmai injection was not selected. This inter provincial alliance focused on purchasing with quantity.
1、 Basic information of Shenmai injection of the company
Drug name specification function indications
Shenmai injection is a drug for cardiovascular diseases. It is mainly used to treat 100ml / bottle, shock with deficiency of Qi and Yin, coronary heart disease, viral myocarditis, 50ml / bottle of Shenmai injection, chronic cor pulmonale and granulocytopenia. It can improve the immune function of tumor patients by 10ml * 5 Sticks / box. It is a category a product of national catalogue of essential drugs and national medical insurance proprietary Chinese medicine.
Note: the specifications of Shenmai injection purchased by the inter provincial alliance of Chinese patent medicine are 100ml / bottle, 50ml / bottle, 20ml / piece and 20ml * 3 pieces / box.
2、 Impact of failure of Shenmai Injection on the company
In 2020, the sales of Shenmai injection was 43.1727 million yuan, accounting for 20.21% of the company’s operating revenue, including Hubei, Hebei, Shanxi, Inner Mongolia, Liaoning, Fujian, Jiangxi, Henan, Hunan, Hainan, Chongqing, Sichuan, Guizhou, Tibet, Shaanxi, Gansu, Ningxia, new The sales of Shenmai injection in Xinjiang Corps (hereinafter referred to as “19 provinces and regions”) and other regions is about 24.8 million yuan, accounting for 11.64% of the company’s operating revenue; from January to September 2021, the sales of Shenmai injection is about 18.9 million yuan, accounting for 14.65% of the company’s operating revenue, of which the sales of Shenmai injection in 19 provinces and regions is about 11.5 million yuan, accounting for 8.91% of the company’s operating revenue.
The centralized procurement cycle of inter provincial alliance of Chinese patent medicine is two years. This failure may have a certain impact on the sales of Shenmai injection in the above 19 provinces and regions in the next two years.
3、 Response measures of the company
For the regions and products not selected, on the one hand, the company continues to pay attention to the local bidding process, continues to sort out and optimize the marketing network and customer group structure, and studies the provincial medical insurance policies and bidding schemes. On the other hand, with the support of the company’s academic promotion, re sort out the existing products, actively develop blank medical institutions in combination with the company’s current sales model, and urge the sales personnel to strengthen the development of the third end market such as private hospitals.
Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Dali Pharmaceutical Co.Ltd(603963) board of directors December 24, 2021
